https://scholars.lib.ntu.edu.tw/handle/123456789/543436
標題: | JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions | 作者: | Yoshino T. Pentheroudakis G. Mishima S. Overman M.J. KUN-HUEI YEH Baba E. Naito Y. Calvo F. Saxena A. Chen L.-T. Takeda M. Cervantes A. Taniguchi H. Yoshida K. Kodera Y. Kitagawa Y. Tabernero J. Burris H. Douillard J.-Y. |
關鍵字: | microsatellite instability; mismatch repair; NTRK; recommendations; tumour-agnostic | 公開日期: | 2020 | 出版社: | Elsevier Ltd | 卷: | 31 | 期: | 7 | 起(迄)頁: | 861-872 | 來源出版物: | Annals of Oncology | 摘要: | A Japan Society of Clinical Oncology (JSCO)-hosted expert meeting was held in Japan on 27 October 2019, which comprised experts from the JSCO, the Japanese Society of Medical Oncology (JSMO), the European Society for Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), and the Taiwan Oncology Society (TOS). The purpose of the meeting was to focus on what we have learnt from both microsatellite instability (MSI)/deficient mismatch repair (dMMR) biomarkers in predicting the efficacy of anti-programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) immunotherapy, and the neurotrophic tyrosine receptor kinase (NTRK) gene fusions in predicting the efficacy of inhibitors of the tropomyosin receptor kinase (TRK) proteins across a range of solid tumour types. The recent regulatory approvals of the anti-PD-1 antibody pembrolizumab and the TRK inhibitors larotrectinib and entrectinib, based on specific tumour biomarkers rather than specific tumour type, have heralded a paradigm shift in cancer treatment approaches. The purpose of the meeting was to develop international expert consensus recommendations on the use of such tumour-agnostic treatments in patients with solid tumours. The aim was to generate a reference document for clinical practice, for pharmaceutical companies in the design of clinical trials, for ethics committees in the approval of clinical trial protocols and for regulatory authorities in relation to drug approvals, with a particular emphasis on diagnostic testing and patient selection. ? 2020 European Society for Medical Oncology |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85084431012&doi=10.1016%2fj.annonc.2020.03.299&partnerID=40&md5=125ca404a402f4e26f508a9e80ec918d https://scholars.lib.ntu.edu.tw/handle/123456789/543436 |
ISSN: | 0923-7534 | DOI: | 10.1016/j.annonc.2020.03.299 | SDG/關鍵字: | atezolizumab; biological marker; brain derived neurotrophic factor receptor; ipilimumab; nivolumab; pembrolizumab; Article; cancer immunotherapy; clinical practice; colon cancer; consensus development; diagnostic test; drug approval; drug industry; endometrium cancer; gene fusion; human; microsatellite instability; NTRK1 gene; oncogene; patient selection; priority journal; prostate cancer; solid malignant neoplasm; transitional cell carcinoma; consensus; genetics; Japan; neoplasm; oncology; Taiwan; Consensus; Humans; Japan; Medical Oncology; Microsatellite Instability; Neoplasms; Taiwan |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。